HAVCR2 and ovarian neoplasm: While PD-1 and CTLA-4 blockade has revolutionized treatment in some malignancies [108,109,236], ovarian tumors frequently deploy multiple redundant checkpoint pathways, including TIM-3, LAG-3, and TIGIT, to evade immune attack [148,149,169].